Tag Archives: Life Sciences

← Older posts Newer posts →

Invetx Appoints Bill Brondyk, Colin Giles to Executive Team

Invetx has appointed Bill Brondyk to serve as its chief scientific officer. His experience includes posts at Ohana Therapeutics and Sanofi (NYSE: SNY). Boston-based Invetx also named Colin Giles, a veteran of Nexvet Biopharma and Pfizer Animal Health, to become its chief development officer. Invetx uses the science underlying biologic drugs for humans to develop […]

Posted in Boston | Tagged , | Comments Off on Invetx Appoints Bill Brondyk, Colin Giles to Executive Team

Thrive Earlier Detection Taps CVS’s Asgarian as Chief Medical Officer

Cancer diagnostics developer Thrive Earlier Detection has named Sam Asgarian its chief medical officer. He joins Thrive from CVS Health (NYSE: CVS), where he was vice president of the company’s transformation health product divison. He came to CVS via its acquisition of Aetna. In other moves, Dina Ciarimboli, who had been serving as interim general […]

Posted in Boston | Tagged , | Comments Off on Thrive Earlier Detection Taps CVS’s Asgarian as Chief Medical Officer

Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China

CStone Pharmaceuticals has touted its experimental drug sugemalimab as potentially the best in its class of cancer immunotherapies. Pfizer is placing a bet on that promise by making a $200 million equity investment in CStone for rights to that drug in China. According to deal terms announced late Tuesday, Pfizer (NYSE: PFE) is purchasing nearly […]

Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China

With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug

Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several inherited forms of the disorder. On Wednesday, New York-based Ovid (NASDAQ: OVID) reported Phase […]

Posted in Europe blog main, Europe top stories, National blog main, National top stories, New York, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug

Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins

Orphazyme has fresh cash from the sale of shares in the US and Europe, which will support its lead rare disease drug through regulatory review and, if approved, a launch. But the drug fell short in key clinical trial measures, raising questions about its approvability. Now the FDA wants additional data, potentially throwing a wrench […]

Posted in Europe, Europe blog main, Europe top stories, National blog main | Tagged , , , , , , , , , , , , , , , | Comments Off on Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins

Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs

Praxis Precision Medicines kept mostly quiet about its research on central nervous system disorder (CNS) drugs until May, when it emerged from stealth and revealed $100 million in cumulative financing. Now the company is aiming to raise about that amount in an IPO that will fund clinical development of its drug pipeline. Cambridge, MA-based Praxis […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs

Ex-Radius Health Exec Carmona Joins Rubius as Chief Financial Officer

Rubius Therapeutics (NASDAQ: RUBY) has appointed Jose “Pepe” Carmona to serve as its chief financial officer, the same position he held most recently at Radius Health (NASDAQ: RDUS). Cambridge, MA-based Rubius is engineering red blood cells into potential therapies. Earlier this year, Rubius stopped work on its lead drug candidate for a rare metabolic disorder […]

Posted in Boston | Tagged , | Comments Off on Ex-Radius Health Exec Carmona Joins Rubius as Chief Financial Officer

Freeline Therapeutics Promotes Corbau to Chief Scientific Officer

Gene therapy developer Freeline Therapeutics (NASDAQ: FRLN) has promoted Romuald Corbau to chief scientific officer. He joined London-based Freeline in 2017 as vice president of research. Amit Nathwani, the company’s founder and outgoing chief scientific officer, will remain with the company as clinical and scientific adviser and member of the board of directors. Freeline is […]

Posted in Europe | Tagged , | Comments Off on Freeline Therapeutics Promotes Corbau to Chief Scientific Officer

Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward

Had things turned out differently, scientists at Galecto might be watching their idiopathic pulmonary fibrosis drug candidate develop in the hands of a big pharmaceutical company. But Bristol Myers Squibb passed on its option to acquire Galecto leaving the biotech to forge ahead on its own. Now the company has $64 million to advance clinical […]

Posted in Boston blog main, Boston top stories, Europe, Europe blog main, Europe top stories, National blog main, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward

Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More

In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in an $8 billion cash and stock deal. Grail set out with the goal of developing a diagnostic test that detects cancer from the genetic snippets tumors […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More← Older posts Newer posts →